

1      **Combination low dose sulphonylurea and DPP4**  
2           **inhibitor have potent glucose lowering effect**  
3           **through augmentation of beta cell function**  
4           **without increase in hypoglycaemia: a**  
5           **randomised crossover study.**

6                                      Cordiner RLM <sup>1</sup>, Bedair K <sup>1</sup>, Mari A <sup>2</sup>, Pearson ER<sup>1</sup>

7           <sup>1</sup> Division of Population, Health and Genomics, Ninewells Hospital and Medical School, University of  
8           Dundee, United Kingdom

9           <sup>2</sup> Institute of Neuroscience, National Research Council, University of Padua, Italy

10      **Corresponding Author**

11      Professor Ewan Pearson

12      Professor of Diabetic Medicine

13      Head of Division, Division of Population, Health, and Genomics

14      Ninewells Hospital and Medical School

15      University of Dundee

16      DD1 9SY

17      Email: [e.z.pearson@dundee.ac.uk](mailto:e.z.pearson@dundee.ac.uk)

18      Telephone: +44 1382 383 387

19      ORCID ID Professor Pearson: 0000-0001-9237-8585

20      ORCID ID Dr Ruth Cordiner: 0000-0002-3022-2451

21      Word Count: 4003

22      Tweet: Cordiner et al establish that combination of low dose sulphonylurea (20mg Gliclazide) and  
23      DPP4i have potent glucose lowering effect through augmentation of beta-cell function without  
24      increase in hypoglycaemia. @CordinerRuth @ezpearson @UoDMedicine

25 ClinicalTrials.gov: NCT04192292

## 26 Abstract

### 27 Aims/Hypothesis.

28 It is important to address our use of cheaper generic therapies as the global prevalence of type 2  
29 diabetes (T2DM) will surpass 600 million by 2035. Negative aspects of SU may be avoided by their  
30 use at low dose. We have previously shown that 20mg standard release gliclazide reduces plasma  
31 glucose through augmentation of the classical incretin effect, increased beta-cell glucose sensitivity  
32 and late-phase incretin potentiation. We hypothesised that there would be potential synergy  
33 between low dose SU when given in combination with a DPP4i, without increased hypoglycaemia  
34 risk, and aimed to assess this in a randomised clinical trial.

### 35 Methods

36 30 participants with T2DM (HbA1c <64 mmol/mol) treated with diet or metformin monotherapy  
37 were recruited to a single-centre, open-label, randomised crossover study. Participants completed  
38 four, 14-day study periods in a random order: control, gliclazide 20mg once daily (SU), sitagliptin  
39 100mg (DPP4i), or combination (SUDPP4i). A 2-hour mixed meal tolerance test was conducted at the  
40 end of each block. Beta-cell function was assessed by modelling. The primary outcome was the  
41 effect of treatment on beta-cell glucose sensitivity. Secondary end points included frequency of  
42 blood glucose <3mmol/l on continuous glucose monitoring, sub analysis by genotype (*KNCJ11 E23K*),  
43 and analysis by gender and body mass index.

### 44 Results

45 Linear mixed model estimates showed a potent additive, glucose lowering effect of low dose SU  
46 combination with DPP4. Mean glucose AUC (mean 95% CI) (mmol/l) was: Control 11.5 (10.7 – 12.3),  
47 DPP4i 10.2 (9.4 – 11.1), SU 9.7 (8.9 – 10.5), SUDPP4i 8.7 (7.9 – 9.5) ( $p < 0.001$ ). Beta-cell glucose  
48 sensitivity ( $\text{pmol min}^{-1} \text{m}^{-2} \text{mM}^{-1}$ ) mirrored this additive effect: Control 71.5 (51.1 – 91.9), DPP4i 75.9  
49 (55.7 – 96.0), SU 86.3 (66.1 – 106.4), SUDPP4i 94.1 (73.9 – 114.3) ( $p = 0.04$ ). Glucose time in range  
50 <3mmol/l on CGM (%) was unaffected: Control 1 (2-4), DPP4i 2 (3-6), SU 1 (0-4), SUDPP4i 3 (2 – 7) ( $p$   
51 = 0.65). The increase in glucose sensitivity with sulphonylurea treatment was seen in men not  
52 women.

### 53 Conclusions

54 Combination low dose gliclazide with a DPP4i has potent glucose lowering effect through  
55 augmentation of beta cell function. Glucose reduction was achieved at gliclazide concentrations far  
56 below those achieved with standard therapeutic doses. A double-blind randomised controlled trial

57 is merited to formalise efficacy and safety of this combination, which may avoid negative aspects of  
58 SU and provide pharmaco-economic benefit in diabetes care.

59

## 60 Research in Context

### 61 What is already known about this subject?

62 Previous isoglycaemic clamp studies in low dose sulphonylureas established that 20mg of gliclazide  
63 augments the classical incretin effect, increases glucose sensitivity by 50% and late phase incretin  
64 potentiation.

### 65 What is the key question?

66 What is the effect of low dose sulphonylureas as monotherapy or in combination with a DPP4i on  
67 parameters of beta cell function following a mixed meal?

### 68 What are the new findings?

69 Low dose sulphonylureas have potent glucose lowering potential which is further enhanced by the  
70 addition of a DPP4i, without increasing hypoglycaemia.

71 Modelling of beta cell function demonstrates that low dose sulphonylureas heighten the beta cell  
72 dose response which is further augmented by the presence of a DPP4i.

73 Phenotypic differences in response are noted, with male participants showing additional effect of  
74 glucose sensitivity in response to sulphonylureas. This effect is not seen in women.

75 Gliclazide standard release at 20mg produces a similar pharmacokinetic profile during mixed meal  
76 tolerance test to 30mg of modified release gliclazide.

### 77 How might this impact on clinical practice in the foreseeable future?

78 These results suggest that it is possible to modernise the use of two cheap, effective second-line  
79 treatments of type 2 diabetes mellitus through future production of a combined preparation of low  
80 dose gliclazide and a DPP4i. This combination has real potential as a safe, efficacious treatment  
81 which could bring pharmacoeconomic benefit to low- and middle-income countries worldwide.

82

## 83 Introduction (Current 4003).

84 Sulphonylureas (SU) have been utilised in the treatment of type 2 diabetes mellitus (T2DM) for over  
85 70 years (1). However, their use has declined due to their associations with hypoglycaemia, weight  
86 gain, limited durability, and their lack of positive cardiovascular outcome data in comparison with  
87 newer agents. Currently, international guidelines recommend the use of SU “if cost is an issue” (2).  
88 However, the cost of diabetes care is escalating; the global prevalence of T2DM is predicted to  
89 increase from 382 million people to 592 million by 2035, which includes 69% increase in prevalence  
90 in developing countries and a 20% increase in developed countries (3, 4). The predicted absolute  
91 global economic burden of diabetes care will increase from \$1.3 trillion US Dollars (95% confidence  
92 interval 1.3 – 1.3) in 2015 to \$2.2 trillion (2.2 – 2.3) in 2030, which translates to an increase in costs  
93 as a share of the global GDP from 1.8% (1.7 – 1.9) in 2015 to a maximum of 2.2% (2.1 – 2.2) (5). This  
94 increase in per capita cost therefore poses a global emergency to control cost. A systematic review  
95 indicated that the economic burden of diabetes most directly affects patients in low- and middle-  
96 income countries (LMIC), with the magnitude of cost differing considerably between countries (6).  
97 Therefore, there is pharmaco-economic need to provide cost-effective diabetes care, including how  
98 we modernise our use of our cheaper generic therapies such as SU and DPP4 inhibitors (DPP4i).

99 Studies in neonatal diabetes mellitus (NDM) have provided insight into the beta-cell response of SU.  
100 Studies in patients with NDM due to activating mutations in *KCNJ11*, found that these patients were  
101 able to effectively switch from insulin to high dose SU, with resulting tight glycaemic control whilst  
102 avoiding hypoglycaemia. Patients with NDM have no insulin response to intravenous glucose but  
103 have a significantly increased insulin response to oral glucose or mixed meal stimulus following SU  
104 initiation, suggesting augmentation of the incretin effect (7, 8). In addition, a supra-additive effect of  
105 SU in combination with high concentrations of intravenous GIP has also been shown in HNF1A-  
106 maturity onset diabetes of the young (HNF1A MODY) (9) and in T2DM treated with standard dose  
107 glipizide (10). Our previous work has shown that low dose SU augment the incretin effect (11). Using  
108 isoglycaemic clamps in patients with T2DM treated with diet or metformin monotherapy, we  
109 demonstrated that a 20mg dose of gliclazide reduced mean glucose AUC during oral glucose  
110 tolerance test from 12.0 to 10.8 mmol/l ( $p=0.0006$ ), augmented the incretin effect from 35.5 to 55%  
111 ( $p=0.04$ ), and increased glucose sensitivity by 50% ( $p=0.01$ ) and enhanced late phase incretin  
112 potentiation ( $p=0.04$ ).

113 Given that we have uncovered a novel mechanism of SU at low dose that results in glucose regulated  
114 insulin secretion, in part mediated by the incretin effect, we hypothesised that DPP4i, which increase  
115 endogenous incretins, would be a potent drug to combine with low dose SU. We aimed to explore

116 the efficacy of low dose SU and endogenous incretins, as monotherapy, and in combination with a  
117 DPP4i on parameters of beta cell function utilising multiple mixed meal tolerance tests (MMT), beta  
118 cell modelling and continuous glucose monitoring (CGM).

## 119 Methods

### 120 Recruitment

121 30 participants were recruited with physician diagnosed T2DM treated with diet or metformin  
122 monotherapy, HbA1c <64 mmol/mol, aged  $\geq 40$  and  $\leq 80$  years and with renal and hepatic function  
123 in the biochemical reference range from local laboratories. To avoid heterogeneity within the  
124 cohort, only White British participants were recruited. All participants had capacity to express  
125 informed, written consent. Participants not meeting inclusion criteria were excluded. Patients who  
126 were pregnant, lactating or planning to conceive within the study period were ineligible. Patients  
127 participating or who were recruited in a clinical study within the preceding 30 days were also  
128 ineligible.

### 129 Study Design

130 We undertook a single-site, open label, randomised crossover study involving MMT (Figure 1). The  
131 study was approved by The East of Scotland Research Ethics Committee (REC 18/ES/0092) and  
132 registered with ClinicalTrials.gov (NCT04192292). All research was conducted in accordance with the  
133 Declaration of Helsinki, and informed written consent was obtained for all participants prior to study  
134 inclusion.

135 Study visits took place at The Clinical Research Centre, Ninewells Hospital and Medical School. The  
136 study involved four intervention blocks, each of 14-days duration, to assess response following  
137 different combination of low dose SU or DPP4i: no intervention (no change to standard care), low  
138 dose SU (20mg gliclazide once daily), DPP4i (100mg sitagliptin once daily), low dose SU + DPP4i  
139 (20mg gliclazide + 100mg sitagliptin once daily).

140 Participants attended the research centre on 6 separate visits. A screening visits confirmed eligibility  
141 and obtained informed written consent. The second visit provided education regarding study drugs,  
142 self-monitoring of blood glucose, and hypoglycaemia. The other four visits were performed at the  
143 end of each block.

144 Participants underwent a 2-hour MMT at the end of each block. Participants were fasted for 8-hours  
145 prior to intervention and all regular medications, including metformin, were withheld until the end  
146 of the test. On arrival to the centre, a single intravenous (IV) cannula was inserted into the  
147 participant's arm for blood sampling. For MMT involving study drug, participants took the study drug

148 on arrival at the research centre. After 60 minutes, a standard liquid meal (Fortisip Compact,  
149 Nutricia, NL) was given. Blood samples for insulin, C-peptide and glucose were taken at 7 defined  
150 time points: 0, 15, 30, 35, 60, 90 and 120 minutes. A single sample for Total GLP-1, GIP and glucagon  
151 concentrations was taken at time 0. Plasma concentrations of gliclazide were sampled at time 0, 60,  
152 and 120 minutes in all participants (n=30); 9 participants were consented to complete a prolonged  
153 MMT for further sampling at 4, 8 and 24 hours for gliclazide pharmacokinetic profiling. The end of  
154 study was determined as last patient last visit.

## 155 **Materials**

### 156 **Study Drugs**

157 Gliclazide 40mg tablets were sourced from Alliance Pharmaceuticals (UK) and halved by Tayside  
158 Clinical Trials Pharmacy. The DPP4i was sitagliptin in the form of Januvia 100mg tablets (Merck Sharp  
159 and Dohme Ltd, UK). A 100mg once daily dosing schedule was chosen as pharmacokinetic studies in  
160 healthy individuals showed a more consistent DPP4 inhibition profile over a 24-hour period. In  
161 comparison, a 50mg dose only provided 12-hours of consistent DPP4 inhibition (12).

### 162 **Liquid Meal**

163 The liquid meal comprised 160ml of Fortisip Compact, the nutritional content for the given volume  
164 was: 184 kilocalories, protein 15.36 grams, carbohydrate 47.52 grams, fat 14.88 grams, nil fibre.

### 165 **Continuous Glucose Monitors**

166 The Freestyle Libre Pro Flash Continuous Glucose Monitoring System was used throughout study  
167 (Abbott).

### 168 **Blood Collection**

169 All blood collection was performed utilising BD Vacutainer systems (Becton, Dickinson and Company,  
170 NJ, USA). Samples were iced following collection and centrifuged immediately in accordance with  
171 recommended guidance from receiving laboratories.

## 172 **Laboratory Analyses**

### 173 **Insulin and C-Peptide**

174 Analysis of insulin and C-peptide was performed by Clinical Chemistry, Royal Devon, and Exeter  
175 Hospital – 602 modules Cobas 8000 automated platform using sandwich chemiluminescence  
176 immunoassay (Elecsys insulin, Belgium)

## 177 Glucose

178 Glucose analysis was performed by NHS Tayside Blood Sciences at Ninewells Hospital utilising  
179 Siemens ADVIA Chemistry, Glucose Hexokinase\_3 Concentrated Reagents (UK).

## 180 Glucagon

181 Glucagon analysis was performed by the Immunoassay Core Biomarker Laboratory, University of  
182 Dundee, utilising EMD Millipore glucagon radioimmunoassay kit (Merck, Billerica, MA, USA).

## 183 Incretins

184 Total GLP-1 and GIP analyses were performed by the Immunoassay Core Biomarker Laboratory,  
185 University of Dundee, utilising MSD metabolic assay Total GLP-1 and GIP assay (MSD, MD, USA).

## 186 Gliclazide

187 Gliclazide analysis was performed by the Biomarker and Drug Analysis Core Facility, University of  
188 Dundee utilising a uniquely developed gliclazide quantification method in human plasma by liquid  
189 chromatography separation, and tandem mass spectrometry analysis.

## 190 Data and Statistical Analyses

### 191 Study Outcomes

192 The statistical analysis is included in Supplementary Information. The primary outcome was the  
193 change in glucose sensitivity at MMT. Secondary outcomes included: the effect of treatment on  
194 parameters of beta-cell function, biochemical parameters (glucose, insulin, c-peptide, and incretin  
195 hormones) and the pharmacokinetic profile of low dose gliclazide. The frequency of blood sugar  
196 levels <3mmol/l on CGM, and the effect of *KCNJ11* (E23K) genotype and gender on change in glucose  
197 sensitivity with drug treatment were also evaluated.

### 198 Randomisation

199 Participants were randomised to intervention order using an unblinded web-based randomisation  
200 software ([www.randomisation.com](http://www.randomisation.com)). A copy of the randomisation plan was stored in the research  
201 centre, Tayside Clinical Trials Pharmacy, and the site file.

### 202 Power

203 Based on previous data in T2DM, the standard deviation of the difference in AUC glucose between  
204 placebo and vildagliptin treatment was 125mmol/l over 240 minutes (13). With 30 patients, the  
205 study would have 80% power ( $p=0.05$ ) to detect a difference of 1/3 of that seen with vildagliptin  
206 alone compared with placebo. Similarly, the power would be enough to detect approximately 50% of  
207 the difference in  $AUC_{INSULIN}:AUC_{GLUCOSE}$  ratio seen comparing vildagliptin and placebo.



## 208 Modelling

209 Two models were developed, a linear mixed effects model and a generalised additive model, both of  
210 which considered the hierarchical nature of the study design of three levels: treatment (n=4),  
211 participant (n=30) and time within the MMT (n=7 time points per MMT). Participants were  
212 randomised to block order and the MMT took place on either day 14, 28, 42 or 56 from the start of  
213 study.

### 214 *Linear Mixed Model with Random Effect*

215 For the primary outcome a linear mixed effects model was applied (14) with glucose sensitivity as  
216 the dependent variable. Synergy was evaluated via post-hoc pairwise comparisons between  
217 treatments. In this model, treatment intervention was considered a fixed effect, as was time within  
218 the MMT. Inter-subject variability, block randomisation and day of MMT were considered as random  
219 effects. Finally,  $\eta$  accounted for all other random effects. All assumptions of linear mixed effect  
220 model residuals were checked for deviation from homoscedasticity or normality.

### 221 *Generalised Additive Model*

222 As the time course of the insulin, c-peptide, incretin, and glucagon response across the MMT were  
223 considered as non-linear parameters, a generalised additive model was developed (15). In this  
224 analysis, “*Treatment*” was considered as a fixed effect whereas “*Time*” was considered as a fixed,  
225 non-linear effect. The model applied smoothing parameters to random effects of inter-subject  
226 variation, block randomisation and day. The model fit was checked using the “*mgcv*” package in R  
227 (15).

## 228 Parameters of Beta Cell Modelling

229 Beta cell function was assessed using a previously described model (16, 17)(18), designed to analyse  
230 the MMT tests. The model describes the relationship between insulin secretion and glucose  
231 concentration by means of a dose-response function relating the two variables and an early  
232 secretion component. The dose-response is characterised by its average slope, termed glucose  
233 sensitivity, and early secretion by a parameter denoted as rate sensitivity, a marker of early phase  
234 insulin release. The dose response function is modulated by a time-varying potentiation factor,  
235 which accounts for effects of sustained hyperglycaemia and incretins. The potentiation factor  
236 excursion was calculated as the ration between the values at the end of the 2-h OGTT and at  
237 baseline.

## 238 Data Presentation

239 Model results are presented in tables of estimates (mean (95% confidence intervals)), standard  
240 error, test statistic and *P*-value. A significant *P*-value result provided in the “*Control*” arm represents

241 that the intercept is significantly different to 0. *P*-values for treatment interventions demonstrate  
242 statistical significance versus control.

## 243 Statistical Software

244 Data were managed utilising Microsoft Excel as part of Microsoft Office 365 Pro Plus Version 1908  
245 (Build 11929.20708). Statistical analysis and graphical presentation were performed in R (19).

## 246 Results

### 247 Baseline Characteristics

248 Study recruitment ran from September 2019 to September 2020. All study activity was paused due  
249 to COVID-19 pandemic between March and August 2020. Two participants withdrew consent for  
250 study immediately after screening in March 2020 due to the COVID-19 pandemic; these participants  
251 were replaced. One participant withdrew prior to last MMT due to circumstances unrelated to study;  
252 data until point of withdrawal were retained as per study consent.

253 Baseline characteristics of the study cohort ( $n=30$ ) were representative of SU users in the Tayside  
254 region (Table 1). In a sub-analysis by gender, male participants had lower BMI (median (LQ, UQ))  
255 (Male 30.5 (25, 33) vs Female 39 (31, 41)  $\text{kg/m}^2$  ( $p<0.001$ )) and were older (Male 67.5 (64, 71) vs  
256 Female 59 (54, 66) years, ( $p = 0.02$ ). The most common concomitant medications were metformin  
257 ( $n=27$ ), statins ( $n=26$ ), proton pump inhibitors ( $n=13$ ) and selective serotonin reuptake inhibitors  
258 (11).

259 Adverse events included one episodes of symptomatic hypoglycaemia (BM 3.3 mmol/l) which  
260 occurred on DPP4-inhibitor monotherapy. There were 14 occurrences of detachment of CGM  
261 sensors which were documented as adverse events. Sensors were replaced on the next working day  
262 following report to the study team.

### 263 Primary Outcome: change in glucose sensitivity with treatment.

264 Linear mixed model parameters of beta cell function are summarised in Table 2. The plot of glucose  
265 sensitivity suggests additive effect of treatment (Figure 2A). However, the linear mixed model  
266 estimates only show difference in glucose sensitivity with SUDPP4i compared to baseline ( $p=0.04$ )  
267 (Table 2).

268 Figure 3 shows the model-determined relationship between insulin secretion and glucose  
269 concentration in each of the four intervention groups. A progressive increase in slope is observed  
270 across the treatments, representative of the corresponding increase in glucose sensitivity. A left shift  
271 is noted in favour of combination treatment in both glucose sensitivity and insulin secretion at

272 8mmol/l (Figure 2B), demonstrating augmentation of beta cell function at lower glucose  
273 concentrations.

## 274 Secondary Outcomes

275 Rate sensitivity, which is a marker of early insulin release, was augmented by both gliclazide  
276 interventions (Figure 2C, Table 2). This is expected, as gliclazide is a secretagogue influencing early  
277 insulin secretion. Predictably, this effect was not further augmented by the combination with DPP4i.

278 There was no difference in potentiation factor ratio (Table 2). The trend towards an increase in  
279 SUDDP4i suggests that had the MMT been prolonged (Figure 2D), difference may have been  
280 observed in late phase potentiation as in our previous study on the incretin effect, which lasted four  
281 hours (11).

## 282 Glucose

283 The mean fasting and mean glucose AUC were reduced in all treatment groups compared with  
284 control (Figure 4). Linear mixed modelling outcomes showed additive effect in terms of difference  
285 between estimates of both DPP4i and SU groups versus SUDPP4i (Table 3). SUDPP4i reduced mean  
286 glucose AUC compared with both treatments as monotherapy.

## 287 Insulin and C-Peptide

288 The generalised additive model estimates showed no effect of treatment on either incremental AUC  
289 (iAUC) insulin or C-peptide (Table 2). However, when interpreted in context of significant glucose  
290 reduction, this would suggest an overall improvement in beta cell function (Table 3).

## 291 Incretins

292 As our previous work found that low dose gliclazide had no impact on dynamic endogenous incretin  
293 or glucagon secretion (11), only fasting measurements were performed. Generalised additive model  
294 estimates showed that SU reduced fasting GLP-1, GIP, and glucagon concentrations (Supplementary  
295 Information Table 1).

## 296 Gliclazide Pharmacokinetics

297 Study drugs were administered 60 minutes prior to the start of the MMT. Mean gliclazide  
298 concentrations (mean (SD)) (ng/ml) were SU 662 (408), SUDPP4i 603 (355) respectively ( $p = 0.31$ )  
299 and maximum concentrations were 749 (433) and 645 (397) ng/ml ( $p=0.01$ ) in the SU and SUDPP4i  
300 meal tests, respectively. Combination treatment did not affect the 24-hour profile of gliclazide:  
301 mean gliclazide AUC 660 (328) and 535 (223) ng/ml ( $p=0.1$ ), maximum concentration 770 (328) and  
302 793 (413) ( $p=0.8$ ). Trough concentrations of gliclazide were 370 (183) and 343 (183) ng/ml in the SU  
303 and combination groups, respectively.

## 304 Continuous Glucose Monitoring

305 Blood glucose <3mmol/l was considered as biochemically significant hypoglycaemia in line with the  
306 European and American joint position statement (21). Linear mixed effects modelling of time in  
307 range (TIR) <3mmol/l on CGM (%) was unaffected: Control 1 (2-4), DPP4i 2 (3-6), SU 1 (0-4) ( $p=0.64$ ).  
308 Only treatments involving SU increased TIR 3-10mmol/l (%) versus control: Control 67.4 (56.6 –  
309 78.2), DPP4i 64.5 (45.6 – 83.74), SU 71.83 (52.59 – 17.25), SUDPP4i 68.4 (66.16 – 85.83) ( $p<0.001$  SU  
310 & SUDPP4i versus control).

## 311 Effect of *KCNJ11* (E23K) Genotype

312 The study cohort included 12 EE, 5 KK and 12 EK heterozygotes, which is slightly higher than the 34 –  
313 48% minor allele frequency reported for Caucasian populations (22). Linear mixed model estimates  
314 showed additive effect of treatment on glucose parameters in EE homozygotes only (Supplementary  
315 Information Table 2) and fasting insulin and C-peptide in those carrying the K-allele. Plots of the  
316 glucose sensitivity suggest a steeper slope in K-allele carriers (Figure 5); however, the linear mixed  
317 model estimates were not statistically significant.

## 318 Effect of Gender

319 As previous literature had suggested differing response to SU by sex and BMI (23), the model was  
320 adjusted for this interaction. Sub analysis of glucose sensitivity and the dose response revealed a  
321 potent additive effect in male participants, which was not observed in female participants (Figure 6).  
322 Linear mixed modelling estimates suggest that women respond better to DPP4is, which has not been  
323 previously documented, with no difference in glucose lowering effect between DPP4i and SU. In  
324 contrast, men showed a greater response to interventions involving SU, including between SU and  
325 combination treatment (Supplementary Information Table 3).

## 326 Discussion

327 The study describes the effect of low dose SU as monotherapy, or in combination with a DPP4i on  
328 parameters of beta-cell function in response to a standardised meal with four different  
329 interventions: control, 100mg sitagliptin, 20mg gliclazide or both. Our results show that combination  
330 treatment with SU and DPP4i enhanced glucose control and beta-cell function, without  
331 hypoglycaemia on CGM which supports that this combination could have potential use as an  
332 effective, low-cost treatment. However, the observed increase in glucose sensitivity with  
333 combination treatment was not greater than the sum of the monotherapy responses.

334 **Low dose sulphonylureas are potent glucose lowering agents whilst avoiding**  
335 **hypoglycaemia.**

336 In this study, we show that 20mg of gliclazide has potent glucose lowering potential which is further  
337 enhanced by the addition of a DPP4i whilst avoiding hypoglycaemia. A 2.8 (0.305) mmol/l (mean  
338 (SEM)) reduction in mean glucose from AUC was observed with combination treatment versus  
339 control. Strikingly, 20mg of gliclazide as monotherapy was as potent as 100mg sitagliptin (mean  
340 glucose reduction 1.8 mmol/l (0.3), 1.3 (0.3) mmol/l  $p=0.27$  gliclazide vs sitagliptin respectively). A  
341 meta-analysis of studies combining standard dose SU with DPP4i have shown a 50% increased risk in  
342 hypoglycaemia in the first 6 months of treatment (24). We used 20mg gliclazide in this study, which  
343 showed no difference in the frequency of hypoglycaemic events between treatments.

344 We propose mechanistically that low dose SU do not cause hypoglycaemia due to their effect on the  
345  $K_{ATP}$  channel open state, similar to their mechanism observed in *KCNJ11* neonatal diabetes mellitus  
346 (NDM) (25). In *KCNJ11* NDM, high dose glibenclamide is required to promote insulin secretion and  
347 successful transition off insulin (7). Even at these high doses the mutant K channels do not shut  
348 completely, resulting in a beta-cell resting membrane potential that is sub-threshold for insulin  
349 release but primed for other stimuli such as incretins. In T2DM, where there are only minor defects  
350 in  $K_{ATP}$  channel function, normal doses of SU fully close the  $K_{ATP}$  channels resulting in insulin secretion  
351 despite normal or low glucose. Our findings suggest that a very low dose of SU in T2DM achieves a  
352 similar partial closure of the  $K_{ATP}$  channels as seen for high dose SU in NDM, working primarily to  
353 prime the beta-cell to other secretagogues such as the incretins or amino acids, resulting in glucose  
354 regulated insulin secretion and no insulin secretion in the presence of normal or low blood glucose.  
355 Therefore, it could be possible to achieve the glycaemic benefits of SU, whilst minimising negative  
356 attributes.

357 **Combination low dose sulphonylurea and DPP4i heighten parameters of beta**  
358 **cell function with additional effect on glucose lowering.**

359 Modelling of beta cell function showed progressive augmentation of the slope of the dose-response  
360 (glucose sensitivity) in favour of SUDPP4i, however, although there was clear additive effect, there  
361 was no evident synergy as hypothesised. The relationship of the dose-response is presented in  
362 Figure 3; there are two parameters characterising this relationship. The first is glucose sensitivity,  
363 and the second is insulin secretion at fixed glucose concentration, which is equivalent to an  
364 intercept. It may be that the left shift in the dose-response may at least in part be independent of  
365 glucose sensitivity, however in this study significant additive effect is also seen in this parameter. It  
366 can be postulated that SU in this instance are enhancing insulin secretion, but maintaining glucose

367 dependence, thus avoiding hypoglycaemia, as supported by our CGM findings. The impact of  
368 gliclazide on glucose sensitivity has been previously suggested in rat models (26, 27) and in healthy  
369 human participants (28), albeit at high dose.

### 370 Gliclazide pharmacokinetics

371 This study explored the 24-hour plasma concentration profile of 20mg standard release gliclazide,  
372 observing trough concentrations of ~370ng/ml, mean plasma concentrations of 500 - 600ng/ml and  
373 peak of 908 ng/ml. For comparison, an 80mg dose of gliclazide generates peak plasma  
374 concentrations of between 3000 – 5000ng/ml (29). Interestingly the plasma concentrations  
375 observed in this study are only a little lower than those documented for 30mg gliclazide MR: trough  
376 472, mean 800 and maximum concentrations of 1100 ng/ml, respectively. A multi-centre double-  
377 blind RCT compared the efficacy and safety of gliclazide MR vs glimepiride, in a cohort which  
378 included those at higher risk of SH (>65 years and renal impairment). Both groups achieved HbA1c  
379 reduction of 1.0% with fewer hypoglycaemic events with gliclazide MR than glimepiride (3.7 vs 8.9%)  
380 (30), which suggests that low dose modified release preparations may be preferential in terms safety  
381 with similar cost and efficacy to standard release SU.

### 382 Response by Genotype

383 In this study K allele (diabetes-risk allele) carriers showed higher fasting glucose, reduced insulin  
384 secretion and beta cell function. Differences were observed in terms of plasma glucose and beta-cell  
385 function in carriers of the K allele, but there was no difference in the response to treatment. Plots of  
386 the dose response suggest that K-allele carriers have lower fasting insulin secretion, but in the  
387 control group there was a greater slope of glucose sensitivity than EE homozygotes, similar to  
388 previous literature (31). However, the difference in slopes with gliclazide treatment was more  
389 pronounced in EE homozygotes suggesting that the 20mg dose may not be high enough to  
390 sufficiently close the  $K_{ATP}$  channels in K allele carriers to allow the amplifying pathway to operate.  
391 This is supported by a previous study which suggested that K allele carriers require higher doses of  
392 SU to achieve glucose reduction, and even higher doses in KK homozygotes (32). A dose-response by  
393 genotype study would be required to fully investigate this effect.

### 394 Gender differences in response

395 It is interesting that the additive pattern of glycaemic reduction and increase of beta-cell function  
396 with SU or in combination with a DPP4i is only seen in men, but not women. However, sub analysis  
397 shows the additive effect on insulin secretion at 8mmol/l glucose is preserved in women, which does  
398 suggest effect independent of glucose sensitivity in this instance. These differences in physiological  
399 responses by gender mirror findings in large cohort studies (23). In an analysis of subgroups of BMI

400 and gender in patients (n=22,379) starting SU or TZD in the UK Clinical Practice Data Research  
401 Datalink (CPRD), non-obese males (BMI <30) had a 3.3 mmol/mol better response to SU than TZD  
402 (p<0.001), these findings were replicated in the ADOPT study (first-line treatment) (33) and observed  
403 in the RECORD study (34). These studies support that there is a sex difference in SU response, and  
404 our study provides some physiological insights into these differences. Possible explanations include  
405 that the women had higher BMI, although adjusting for BMI does not remove the sex difference  
406 (data not shown); or a sex difference in incretin physiology. The ADDITION-PRO study reported that  
407 women have greater increased serum GLP-1 concentrations following OGTT than men, even after  
408 adjustment for BMI (35). Further studies are warranted to further investigate this.

## 409 Limitations

410 The main limitation in this study is the wide variability in beta-cell response within a small cohort,  
411 which limits power and ability to perform further sub-analysis. However, the population would  
412 reflect those who would merit second-line intensification in real-world medicine. This open-label  
413 physiological study design was adopted as further proof-of-concept prior to undertaking a formal  
414 randomised controlled trial (RCT) The ideal study design would have been a double-blinded RCT, but  
415 this was not feasible at this stage.

416 The advantage of beta-cell modelling is the ability to model static and dynamic parameters of beta-  
417 cell function, beyond traditional measures of glucose and insulin secretion. However, as a more  
418 complicated procedure, involving multiple parameters it may add some estimation error.

## 419 Conclusion

420 We have shown that low dose sulphonylureas are potent glucose lowering agents, which increase  
421 the beta-cell dose response to glucose without increasing hypoglycaemia. This response is further  
422 augmented in the presence of a DPP4 inhibitor, although we did not see synergy with this  
423 combination. A formal randomised controlled trial of the efficacy and safety of a low dose  
424 sulphonylurea in combination with a DPP4 inhibitor is warranted as a combination treatment may  
425 allow modernisation of two cheap, effective treatments of T2DM with considerable potential for  
426 pharmaco-economic benefit worldwide.

## 427 Acknowledgements

428 The authors would like to thank the study team of The Clinical Research Centre, Ninewells Hospital  
429 and Medical School, Dundee: H Loftus, L Cabrelli, G Wilkie, G Kiddie, D Pankhurst and C Shearer.  
430 Thanks to T McDonald and R Nice of the Department of Clinical Chemistry, University of Exeter for  
431 insulin and c-peptide measurements. J Burns of Ninewells Hospital and Medical School, Dundee for

432 measurement of glucose concentrations, J Huang and the Department of Biomarker and Drug  
433 Analysis, University of Dundee for the development of the gliclazide mass spectrometry method and  
434 the Immunoassay Core Biomarker Facility, University of Dundee for incretin and glucagon  
435 measurement.

## 436 Data Availability

437 Some or all datasets generated and/or analysed during the current study are not publicly available  
438 but are available from the corresponding author on reasonable request.

## 439 Funding

440 This research was funded by a New Investigator Award to ERP from Wellcome (102820/Z/13/Z).

## 441 Conflict of Interest

442 RLMC and KB have no conflict of interest to disclose. AM has received research grants from  
443 Boehringer Ingelheim and Eli Lilly and consultancy fees from Eli Lilly. ERP has received honoraria  
444 from Sanofi and Eli Lilly.

## 445 Contribution Statement

446 RLMC and ERP conceived, designed and acquired study data. RLMC, KB and ERP designed the  
447 statistical analysis plan. RLMC undertook statistical analysis with advice from KB, ERP and AM. AM  
448 and AT conducted beta-cell modelling analysis and interpretation. RLMC and EP wrote the initial  
449 drafts of the manuscript, these drafts were revised for important scientific content by all authors. All  
450 authors gave final approval of the version to be published. ERP is the guarantor of this work.

451

452

453



## 454 Figure Legends

### 455 Figure 1

456 Figure 1: Unblinded randomised crossover study design involving four different study intervention  
457 periods, each 14 days duration. Participants completed a 2-hour mixed meal tolerance test at the  
458 end of each study period.

### 459 Figure 2

460 Figure 2: a) Glucose sensitivity b) Insulin Secretion at 8mmol/l glucose c) Rate Sensitivity d)  
461 Potentiation Factor by treatment (Mean (SEM))

### 462 Figure 3

463 Dose response by treatment (Mean (SEM))

### 464 Figure 4

465 Mean (SEM) a) Fasting Glucose b) Glucose from Mixed Meal Test

### 466 Figure 5

467 Dose response to treatment by *KCNJ11 E23K* genotype (Mean (SEM))

### 468 Figure 6

469 Gender Differences in Treatment Response (Mean (SEM)) a) Glucose from Mixed Meal Test

470 b) Glucose Sensitivity c) Insulin Secretion at 8mmol/L Glucose

471

472

473 **Table 1**

Phase of Study	Number of Participants	Gender (M/F)	Pre-Existing Treatment (Diet/Metformin)	Age (Years)	Body Mass Index (Kg/M <sup>2</sup> )	Body Surface Area (M <sup>2</sup> )	HbA1c (mmol/mol)	Duration of Diabetes (Years)
Full Study	30	16/14	3/27	66 (57,70)	32.4 (28.40)	2.1 (1.9, 2.3)	54 (48, 62)	6.5 (4.8, 10.0)
Pharmacokinetic Phase	9	3/6	3/6	66 (64, 72)	30.7 (27, 38)	2.1 (1.7, 2.4)	50 (48, 60)	5 (5, 10.5)

474

475 Table 1: Baseline Characteristics (Median (Lower Quartile, Upper Quartile)).

476 30 Participants were analysed for the primary outcome of study. 9 Participants completed prolonged  
477 mixed meal tolerance tests for 24-hour sampling for low dose gliclazide pharmacokinetic profiling.

478

479

480 **Table 2**

Coefficient	Glucose Sensitivity ( $\text{pmol min}^{-1} \text{m}^2 \text{mM}^{-1}$ )		
	Estimates	Standard Error	P-Value
Control	71.5 (51.6 – 91.4)	10.2	
DPP4i	75.9 (34.3 – 117)	11.0	0.70
SU	86.3 (44.7 – 128)	11.0	0.18
SUDPP4i	94.1 (52.6 – 136)	11.0	0.04
	Rate Sensitivity ( $\text{pmol m}^2 \text{mM}^{-1}$ )		
Control	494 (220 – 769)	140	
DPP4i	611 (-32 – 1260)	188	0.53
SU	914 (270 – 1556)	188	0.03
SUDPP4i	879 (234 – 1522)	188	0.04
	Potentiation Factor		
Control	1.07 (0.95 – 1.19)	0.06	
DPP4i	1.09 (0.81 – 1.37)	0.08	0.79
SU	1.08 (0.80 – 1.36)	0.08	0.86
SUDPP4i	1.17 (0.89 – 1.45)	0.08	0.23

481

482 Table 2: Linear mixed effects modelling results of parameters of beta cell function. Estimates are  
 483 shown as mean (95% confidence intervals). All values are rounded to 3 significant figures. *P*-values  
 484 for treatment interventions demonstrate statistical significance versus control.

485

486

487 **Table 3**

Coefficient	Mean Fasting Glucose (mmol/l)			Mean Glucose from AUC (mmol/l)		
	Estimates (95% CI)	Std Error	P-Value	Estimates (95% CI)	Std Error	P Value
Control	8.59 (7.88 – 9.31)	0.37		11.5 (10.7 – 12.3)	0.42	
DPP4i	7.51 (7.06 – 8.68)	0.23	<0.001	10.25 (8.84 – 11.7)	0.30	<0.001
SU	7.25 (6.09 – 8.42)	0.23	<0.001	9.7 (8.29 – 11.1)	0.30	<0.001
SUDPP4i	6.83 (5.6 – 8)	0.23	<0.001	8.7 (7.29 – 10.1)	0.30	<0.001
	Fasting Insulin (pmol/l)			Fasting C-Peptide (pmol/l)		
Control	170 (117 – 224)	27.1		1503 (1271 – 1735)	118	
DPP4i	137.17 (55.2 – 219)	14.8	0.03	1370 (1016 – 1725)	62.7	0.04
SU	165.46 (83.5 – 199)	14.8	0.76	1495 (1141 – 1620)	62.7	0.9
SUDPP4i	182.24 (99.6 – 265)	15.1	0.42	1615 (1261 – 1969)	62.7	0.07
	Incremental AUC Insulin (nmol/l/min <sup>-1</sup> )			Incremental AUC C-Peptide (nmol/l/min <sup>-1</sup> )		
Control	41.1 (30.4 – 51.7)	5.39		144 (111 – 177)	16.8	
DPP4i	43.0 (18.2 – 34)	7.56	0.71	159 (120 – 131)	19.8	0.45
SU	42.0 (16.4 – 67.6)	7.55	0.90	151 (112 – 224)	19.8	0.72
SUDPP4i	44.3 (18.7 – 70.1)	7.58	0.66	154 (81.2 – 226)	19.8	0.65

488

489 Table 3: Summary of linear mixed model outcomes for glucose and generalised additive model  
 490 outcomes for insulin, and C-peptide from mixed meal tolerance test. Estimates are Mean (95%  
 491 Confidence interval). All values are rounded to 3 significant figures. *P*-values for treatment  
 492 interventions demonstrate statistical significance versus control.

493

494

495

## 496 References

- 497 1. A L. Relations entre la structure moleculaire et l'activite  
498 hypoglycemiante des aminobenzene-sulfamido-alkylthiodiazols. Archives  
499 International Physiology. 1944:174-7.
- 500 2. Introduction: Standards of Medical Care in Diabetes—2019. Diabetes  
501 Care. 2019;42(Supplement 1).
- 502 3. Federation ID. International Diabetes Federation Atlas 2013.
- 503 4. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of  
504 diabetes for 2010 and 2030. Diabetes Research and Clinical Practice.  
505 2010;87(1):4-14.
- 506 5. Bommer C, Sagalova V, Heesemann E, Manne-Goehler J, Atun R,  
507 Bärnighausen T, et al. Global Economic Burden of Diabetes in Adults:  
508 Projections From 2015 to 2030. Diabetes Care. 2018;41(5):963-70.
- 509 6. Seuring T, Archangelidi O, Suhrcke M. The Economic Costs of Type 2  
510 Diabetes: A Global Systematic Review. Pharmacoeconomics.  
511 2015;33(8):811-31.
- 512 7. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin  
513 B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes  
514 due to Kir6.2 mutations. N Engl J Med. 2006;355(5):467-77.
- 515 8. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide Treatment in  
516 Permanent Neonatal Diabetes Mellitus due to an Activating Mutation in Kir6.2.  
517 The Journal of Clinical Endocrinology & Metabolism. 2004;89(11):5504-7.
- 518 9. Christensen AS, Hædersdal S, Storgaard H, Rose K, Hansen NL, Holst  
519 JJ, et al. GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in  
520 Hepatocyte Nuclear Factor 1 $\alpha$  Mutation Carriers. Diabetes. 2020;69(9):1989-  
521 2002.
- 522 10. Aaboe K, Knop FK, Vilsboll T, Volund A, Simonsen U, Deacon CF, et al.  
523 KATP channel closure ameliorates the impaired insulinotropic effect of  
524 glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.  
525 J Clin Endocrinol Metab. 2009;94(2):603-8.
- 526 11. Cordiner RLM, Mari A, Tura A, Pearson ER. The Impact of Low-dose  
527 Gliclazide on the Incretin Effect and Indices of Beta-cell Function. J Clin  
528 Endocrinol Metab. 2021;106(7):2036-46.
- 529 12. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect  
530 of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on  
531 Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in  
532 Patients with Type 2 Diabetes. 2006;91(11).
- 533 13. Ahren B, Pacini G, Foley JE, Schweizer A. Improved Meal-Related -  
534 Cell Function and Insulin Sensitivity by the Dipeptidyl Peptidase-IV Inhibitor  
535 Vildagliptin in Metformin-Treated Patients With Type 2 Diabetes Over 1Year.  
536 Diabetes Care. 2005;28(8):1936-40.
- 537 14. Bates D MM, Bolker B, Walker S "Fitting Linear Mixed-Effects Models  
538 Using LME4". Journal of Statistical Software. 2015;67(1):1 - 48.
- 539 15. SN W. Fast stable restricted maximum likelihood and marginal  
540 likelihood estimation of semiparametric generalized linear models. Journal of  
541 Royal Statistical Society (B). 2011;73(1):3 - 36.

- 542 16. Mari A, Ferrannini E. Beta-cell function assessment from modelling of  
543 oral tests: an effective approach. *Diabetes Obes Metab.* 2008;10 Suppl 4:77-  
544 87.
- 545 17. Mari A, Pacini G, Murphy E, Ludvik B, Nolan JJ. A Model-Based Method  
546 for Assessing Insulin Sensitivity From the Oral Glucose Tolerance Test.  
547 *Diabetes Care.* 2001;24(3):539-48.
- 548 18. Mari A, Tura A, Gastaldelli A, Ferrannini E. Assessing insulin secretion  
549 by modeling in multiple-meal tests: role of potentiation. *Diabetes.* 2002;51  
550 Suppl 1(Supplement 1):S221-6.
- 551 19. R Development Core Team. R: A language and environment for  
552 statistical computing. 4.1.1 ed. Vienna, Austria: R Foundation for Statistical  
553 Computing; 2010.
- 554 20. Mari A, Gastaldelli A, Foley JE, Pratley RE, Ferrannini E. Beta-cell  
555 function in mild type 2 diabetic patients: effects of 6-month glucose lowering  
556 with nateglinide. *Diabetes Care.* 2005;28(5):1132-8.
- 557 21. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should  
558 Be Reported in Clinical Trials: A Joint Position Statement of the American  
559 Diabetes Association and the European Association for the Study of Diabetes.  
560 *Diabetes Care.* 2017;40(1):155-7.
- 561 22. Gonzalez D PM, Johnson J. PharmGKB: Very Important Pharmacogene  
562 KCNJ11 PharmGKB2020 [Available from:  
563 <https://www.pharmgkb.org/vip/PA166169501>.
- 564 23. Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones  
565 AG, et al. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and  
566 Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating  
567 Stratification Using Routine Clinical and Individual Trial Data. *Diabetes Care.*  
568 2018;41(9):1844-53.
- 569 24. Salvo F, Moore N, Arnaud M, Robinson P, Raschi E, De Ponti F, et al.  
570 Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of  
571 hypoglycaemia: systematic review and meta-analysis. *BMJ.* 2016:i2231.
- 572 25. Proks P, De Wet H, Ashcroft FM. Molecular Mechanism of  
573 Sulphonylurea Block of KATP Channels Carrying Mutations That Impair ATP  
574 Inhibition and Cause Neonatal Diabetes. *Diabetes.* 2013;62(11):3909-19.
- 575 26. Patane G, Piro S, Anello M, Rabuazzo AM, Vigneri R, Purrello F.  
576 Exposure to glibenclamide increases rat beta cells sensitivity to glucose. *Br J*  
577 *Pharmacol.* 2000;129(5):887-92.
- 578 27. Dachicourt N, Bailbe D, Gangnerau MN, Serradas P, Ravel D, Portha B.  
579 Effect of gliclazide treatment on insulin secretion and beta-cell mass in non-  
580 insulin dependent diabetic Goto-Kakisaki rats. *Eur J Pharmacol.* 1998;361(2-  
581 3):243-51.
- 582 28. van Haeften TW, Veneman TF, Gerich JE, van der Veen EA. Influence  
583 of gliclazide on glucose-stimulated insulin release in man. *Metabolism.*  
584 1991;40(7):751-5.
- 585 29. Davis TM, Daly F, Walsh JP, Ilett KF, Beilby JP, Dusci LJ, et al.  
586 Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and

- 587 Australian Aborigines with type 2 diabetes. *Br J Clin Pharmacol*.  
588 2000;49(3):223-30.
- 589 30. Zammitt NN, Frier BM. Hypoglycemia in Type 2 Diabetes:  
590 Pathophysiology, frequency, and effects of different treatment modalities.  
591 *Diabetes Care*. 2005;28(12):2948-61.
- 592 31. Zhang H, Liu X, Kuang H, Yi R, Xing H. Association of sulfonylurea  
593 receptor 1 genotype with therapeutic response to gliclazide in type 2 diabetes.  
594 *Diabetes Research and Clinical Practice*. 2007;77(1):58-61.
- 595 32. Rastegari A, Rabbani M, Sadeghi HM, Imani EF, Hasanzadeh A,  
596 Moazen F. Pharmacogenetic association of KCNJ11 (E23K) variant with  
597 therapeutic response to sulphonylurea (glibenclamide) in Iranian patients.  
598 *International Journal of Diabetes in Developing Countries*. 2015;35(4):630-1.
- 599 33. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR,  
600 et al. A diabetes outcome progression trial (ADOPT): an international  
601 multicenter study of the comparative efficacy of rosiglitazone, glyburide, and  
602 metformin in recently diagnosed type 2 diabetes. *Diabetes Care*.  
603 2002;25(10):1737-43.
- 604 34. Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ,  
605 Zambanini A, et al. Effect of the addition of rosiglitazone to metformin or  
606 sulfonylureas versus metformin/sulfonylurea combination therapy on  
607 ambulatory blood pressure in people with type 2 diabetes: a randomized  
608 controlled trial (the RECORD study). *Cardiovasc Diabetol*. 2008;7:10.
- 609 35. Faerch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A,  
610 et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-  
611 Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The  
612 ADDITION-PRO Study. *Diabetes*. 2015;64(7):2513-25.

613




Figure 1: Unblinded randomised crossover study design involving four different study intervention periods, each 14 days duration. Participants completed a 2-hour mixed meal tolerance test at the end of each study period.






Figure 2: a) Glucose sensitivity b) Insulin Secretion at 8mmol/l glucose c) Rate Sensitivity d) Potentiation Factor by treatment (Mean (SEM))




Figure 3: Dose response by treatment (Mean (SEM))




Figure 4: Mean (SEM) a) Fasting Glucose b) Glucose from Mixed Meal Test




Figure 5: Dose response to treatment by *KCNJ11 E23K* genotype (Mean (SEM))




Figure 6: Gender Differences in Treatment Response (Mean (SEM)) a) Glucose from Mixed Meal Test b) Glucose Sensitivity c) Insulin Secretion at 8mmol/L Glucose